Skip to main content

Table 1 Baseline characteristics of study participants included in the analysis

From: Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis

  Study 1 INVOLVE [16] Study 2 INHANCE [17] Study 3 INLIGHT 1 [18] Total
n 1377 1575 361 3313
Age, years 64 (8) 64 (9) 63 (10) 64 (9)
Male/female, % 78/22 63/37 52/48 69/31
Body mass index, kg/m2 27 (5) 27 (6) 28 (7) 27 (6)
FEV1, % predicted* 53 (14) 56 (14) 55 (14) 55 (14)
FEV1/FVC, %* 51 (10) 53 (10) 53 (10) 52 (10)
Pre-bronchodilator FEV1, l 1.35 (0.43) 1.33 (0.49) 1.34 (0.51) 1.34 (0.47)
Post-bronchodilator FEV1, l* 1.52 (0.47) 1.50 (0.50) 1.51 (0.52) 1.51 (0.49)
Reversibility, %* 13.2 (13.4) 15.5 (15.9) 16.0 (18.7) 14.6 (15.3)
ICS use yes/no, % 55/45 38/62 32/68 45/55
Smoker/ex-smoker, % 40/60 44/56 52/48 43/57
BDI score 6.6 (2.2) 6.5 (2.3) NA 6.5 (2.2)
SGRQ total score 44 (18) 45 (18) 49 (19) 45 (18)
Treatments     
   Placebo, n 322 311 176 809
   Indacaterol 75 μg, n 0 67 0 67
   Indacaterol 150 μg, n 0 346 185 531
   Indacaterol 300 μg, n 363 357 0 720
   Indacaterol 600 μg, n 344 68 0 412
   Formoterol 12 μg, n 348 75 0 423
   Tiotropium 18 μg, n 0 351 0 351
  1. Data are mean (standard deviation) unless otherwise stated. *Measured 30 min after salbutamol 400 μg inhalation. Reversibility was calculated as the difference between the pre- and post-bronchodilator values of FEV1 (in l) as a percentage of the pre-bronchodilator value; BDI, Baseline Dyspnoea Index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; INVOLVE, INdacaterol: Value in COPD: Longer term Validation of Efficacy and safety; INHANCE, INdacaterol versus tiotropium to Help Achieve New COPD treatment Excellence; INLIGHT, INdacaterol: efficacy evaLuation usInG 150 μg doses with COPD PatienTs; NA, not available; SGRQ, St George's Respiratory Questionnaire.